Clinical trials: Sedatives
Pain, Postoperative
Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain
The objective of the study is to evaluate the efficacy and safety of a single oral dose of two dose combinations of naproxen sodium and diphenhydramine (DPH) to demonstrate that naproxen sodium/DPH combination provides added…
- Trial name
- Morpheus II (NCT01280591)
- Testing
- Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111), Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111), Naproxen sodium 440 mg (BAYH6689)
- Where
- 2 sites in United States
- Volunteers
- 712 people
- Sponsor
- Bayer
Pain, Postoperative
Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain
The objective of the study is to evaluate the efficacy and safety of a single oral dose of naproxen sodium 440 mg in combination with DPH (diphenhydramine) 25 mg in subjects with postsurgical dental pain and phase advanced sleep.
- Trial name
- Morpheus/DPH (NCT01495858)
- Testing
- Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111), Naproxen Sodium 440 mg (BAYH6689), DPH 50 mg
- Where
- 2 sites in United States
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- Bayer
Abuse Liability of Staccato Alprazolam
Staccato Alprazolam Abuse Liability
Compare the abuse liabilities of Staccato Alprazolam, oral immediate-release alprazolam, and Staccato Placebo.
- Trial name
- NCT00603980
- Testing
- Inhaled alprazolam 0.5 mg, Inhaled alprazolam 1 mg, Inhaled alprazolam 2 mg
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Nova Pneuma Inc.
Sleep
Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine
The objectives of the study are to evaluate the analgesic and hypnotic efficacy of naproxen sodium and diphenhydramine combination when compared to naproxen sodium, diphenhydramine, and an ibuprofen and diphenhydramine combination
- Trial name
- NCT01118273
- Testing
- Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg, Naproxen Sodium 440 mg (BAYH6689), Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- Bayer
Driving Impaired
Driving Simulation to Assess Non-Sedative Effects of Tolperisone
This is a randomized blinded study to assess the sedative effect of 150 mg TID tolperisone and 10 mg TID cyclobenzaprine compared to placebo on simulated driving performance and cognitive functioning in healthy adult volunteers.
- Trial name
- NCT03353922
- Testing
- Cyclobenzaprine 10 Mg Oral Tablet
- Where
- 2 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Neurana Pharmaceuticals, Inc.
Short-term Insomnia
Pilot Study of a Combination Drug Product for Treatment of Short-term Insomnia
The purpose of this study is to evaluate the effect of a combination drug product containing diphenhydramine, zolpidem and lorazepam on total sleep time.
- Trial name
- NCT02671760
- Testing
- SM-1, Comparator
- Volunteers
- 39 people
- Sponsor
- Sequential Medicine Ltd
Abuse Potential
Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience
This will be a randomized, double-blind, double-dummy, placebo- and active controlled, 5 treatment, 10 sequence, 5 period crossover single dose, Williams square design study in healthy adult, non drug dependent male and female…
- Trial name
- NCT04570436
- Testing
- gabapentin 600 mg, gabapentin 1200 mg, gabapentin 1800 mg
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Viatris Specialty LLC
Abuse Potential
An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users
The purpose of this study is to assess the abuse potential of gabapentin enacarbil in healthy adult, non-dependent, recreational drug users.
- Trial name
- NCT06097676
- Testing
- Alprazolam 2 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Arbor Pharmaceuticals, Inc.
Sedation
A Dose-ranging Study to Evaluate the Safety and Efficacy of LUSEDRA (Fospropofol Disodium) as an Intravenous Sedative for Diagnostic or Therapeutic Colonoscopy in Adult Special Populations
The purpose of this study is to evaluate the safety and efficacy of LUSEDRA (fospropofol disodium) and to determine whether a dose lower than currently approved can provide effective moderate sedation required to complete…
- Trial name
- NCT01127438
- Testing
- fospropofol disodium Subgroup 1 Lower Dose, fospropofol disodium Subgroup 1 Approved Dose, fospropofol disodium Subgroup 2 Lower Dose
- Where
- 23 sites in United States
- Volunteers
- 153 people
- Sponsor
- Eisai Inc.